Navigation

Rheumatoid arthritis - abatacept (2nd line)

Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs

Status: History
Expected date of issue: August 2011
Referral date: July 2010
Process: STA
Notes:

Scoped within Batch 12

Topic area:
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Scott Goulden
Communications manager: Tonya Gillis
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 19 November 2010
1st appraisal committee meeting: 02 March 2011
2nd appraisal committee meeting 04 May 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Bristol-Myers Squibb (abatacept)

Patient/carer groups

  • Arthritis Care
  • National Rheumatoid Arthritis Society

Professional groups

  • British Health Professionals in Rheumatology
  • British Society for Rheumatology
  • Primary Care Rheumatology Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Heart of Birmingham Teaching PCT
  • NHS Telford and Wrekin
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • NHS Quality Improvement Scotland

Possible comparator manufacturer(s)

  • Abbott Laboratories (adalimumab)
  • Actavis (azathioprine, sulfasalazine, penicillamine) (removed – no confidentiality form)
  • Alliance Pharmaceuticals (penicillamine)  (removed – no confidentiality form)
  • Almus Pharmaceuticals (sulfasalazine)  (removed – no confidentiality form)
  • Arrow Generics (azathioprine)  (removed – no confidentiality form)
  • Astellas (auranofin)  (removed – no confidentiality form)
  • AstraZeneca (chloroquine)
  • Focus Pharmaceuticals (azathioprine) (removed – no confidentiality form)
  • GlaxoSmithKline (azathioprine)
  • IVAX Pharmaceuticals (azathioprine, sulfasalazine) (removed – no confidentiality form)
  • Kent Pharmaceuticals (azathioprine, sulfasalazine, penicillamine) (removed – no confidentiality form)
  • Mylan (azathioprine, sulfasalazine, penicillamine) (removed – no confidentiality form)
  • Novartis (ciclosporin) (removed – no confidentiality form)
  • Pfizer (sulfasalazine)
  • Sandoz (azathioprine) (removed – no confidentiality form)
  • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
  • Schering-Plough (infliximab, golimumab)
  • Teva UK (azathioprine, sulfasalazine, penicillamine)(removed – no confidentiality form)
  • UCB Pharma (certolizumab pegol)
  • Waymade Healthcare (sulfasalazine) (removed – no confidentiality form)
  • Wyeth Pharmaceuticals (etanercept) (removed – no confidentiality form)

Relevant research groups

  • None

Evidence Review Group

  • School of Health & Related Research Sheffield (ScHARR)
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Clinical Guideline Centre

Associated public health groups

  • Tbc

 

Top


 

Key documents

This page was last updated: 30 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.